Six to nine per cent of white women in Europe and North America will develop breast cancer in their lifetime. Researchers in the USA even talk about a breast cancer epidemic (Greenspan, 1987) . Despite all progress made over the last decades in diagnosis and treatment, overall survival has not significantly increased. The median 10-year survival rate is still less than 50% (Henderson & Canellos, 1980) . Even among a presumably 'low-risk' population like node-negative patients there is a death rate of about 25% over a decade (McGuire et al., 1989) .
At primary therapy less than 10% of all breast cancer patients present with clinically detectable distant tumour spread (Henderson & Canellos, 1980) . Therefore, indirect prognostic criteria such as tumour size, lymph node and receptor status, grading or DNA analysis are used to characterise the individual patient's risk for relapse. Based on this risk analysis, adjuvant systemic therapy is administered. Potentially severe short-and long-term side-effects might be associated with adjuvant therapy. However, recent reports demand an even larger group of patients (i.e. node-negative ones) to be treated in an adjuvant setting (Fisher et al., 1989a; Ludwig Breast Cancer Study Group, 1989) . Better prognostic criteria are therefore urgently needed to identify those patients who will actually benefit from adjuvant therapy. This would allow a more individualised risk-benefit analysis (McGuire et al., 1990) .
One approach to such an improved risk analysis is the search for micrometastatic tumour spread at primary therapy. The skeletal system is the predominant relapse location in breast cancer (Coombes et al., 1983) . It is therefore quite obvious to search there for early distant spread. Conventional biopsies enabled tumour cell detection in the bone marrow of 3.9% apparently metastasis-free patients (Ridell & Landys, 1979) .
This percentage was considerably raised by the use of immunocytochemical methods (Dearnaley et al., 1981) . Encouraged by the results of the London group from the Ludwig Institute (Dearnaley et al., 1981; Redding et al., 1983) Immunocytochemical staining procedure From each aspiration site 4-6 ml of bone marrow was taken. In the first 16 patients the aspirates of each site were analysed separately. However, no correlation between aspiration site and relapse location could be found. Therefore, we then started to pool the aspirates for further preparation. The bone marrow suspension was separated on a Lymphoprep gradient (density 1.077) as described by Boyum (1968 (Kaplan & Meier, 1958) . Optimal cut-off values for the prognostic factor 'tumour size', i.e. for classification of 'small' and 'large' tumours were calculated by the CART method (classification and regression trees) (Segal & Bloch, 1989) and the maximum likelihood method. To compare the predictive value of the prognostic factors for relapse-free as well as overall survival, we performed a multivariate analysis applying 'Cox's propor- tional hazard model' (Cox, 1972) and the BMDP software package (Dixon, 1981 Patients under the age of 50 years were classified as premenopausal and patients of 50 years and older as postmenopausal. None of the prognostic factors showed a statistically significant correlation with the presence of tumour cells.
Correlation with follow-up data Metastasis Table II shows the correlation between tumour cell presence and patient outcome over a median follow-up period of 34 months (maximum 65 months, minimum 7 months). Of the total of 100 patients, 24 (24%) have already relapsed, 14 (14%) at distant sites. Tumour cell-positive patients were at significantly higher risk (P = 0.016) for relapse than tumour cell-negative patients (39% vs 15%). The relapse-free survival data of tumour cell-positive and tumour cell-negative patients is plotted in Figure 1 . Nine of the 38 (24%) tumour cell-positive patients have since relapsed at distant sites compared with 5/62 (8.1%) tumour cell-negative patients. Up till now, no tumour cell-negative patient has relapsed solely in the skeletal system; only one tumour cellnegative patient has relapsed in bone and visceral sites simultaneously. In comparison, in seven tumour cell-positive patients the first site of relapse was bone, in six of whom relapse occurred solely in the skeletal system (see Table II ). This difference is highly significant (P = 0.008). Additionally, within the subgroup of oestrogen receptor-positive patients (n = 56), tumour cell presence in the bone marrow also had a significant impact on survival: relapse-free (P = 0.0086) as well as overall survival (P = 0.0271) was significantly shorter in tumour cell-positive, oestrogen receptor-positive patients. The median interval between tumour cell detection in the bone marrow and metastasis is 11.4 months (maximum 28 months, minimum 1 month). In total, the median relapse-free survival time was 28 months. However, tumour cell-positive patients had a significantly shorter relapse-free survival than tumour cell-negative ones: 19 months vs 33 months (P = 0.0011) (see Table II ).
Survival The overall survival data can be seen in Table III . Sixteen of the total of 100 patients (16%) have already died: nine (24%) in the tumor cell-positive group and seven (11%) in the tumour cell-negative group. In total, the median overall survival time was 33 months, 29 months for tumour cell-positive patients and 36 months for tumour cell-negative patients. The impact of tumour cell presence on overall survival has not yet reached statistical significance (P = 0.0826). Figure 2 shows the overall survival curves of tumour cell-positive and tumour cell-negative patients. aMedian period.
univariate Kaplan-Meier test were considered for multivariate analysis. Since there was a highly significant correlation between tumour size and lymph node status (P = 0.0007), only the clinically more important of these two factors, i.e. lymph node status, was entered into multivariate analysis.
Absence of tumour cells in the bone marrow was the strongest predictor for relapse-free survival (P = 0.0005), even stronger than lymph node status (P = 0.0367). The remaining two parameters, grading and oestrogen receptor status, showed no statistical significance for relapse-free survival (see Table Va ).
Histopathological grading had the highest significant impact (P = 0.0027) on overall survival, closely followed by tumour cell presence (P = 0.0170). However, lymph node involvement and oestrogen receptor status were not statistically significant for the prediction of overall survival (see Table Vb ).
Discussion
The percentage of tumour cell-positive patients (38%) in this study is slightly higher than in our earlier publications (Harbeck et al., 1987; Untch et al., 1988) or the percentage reported by some other groups (Mansi et al., 1987; Schlimok et al., 1987; Porro et al., 1988; Ellis et al., 1989; Diel et al., 1990) . One explanation might be an improved detection rate by using an antibody cocktail instead of a single monoclonal antibody. Using a similar antibody cocktail, Cote et al. (1991) found a similar detection rate of 37%. Unspecific, false-positive staining has been reported with anti-EMA as well as anti-cytokeratin antibodies (Heyderman & McCartney, 1985; Ellis et al., 1989) . This underlines the importance of using both immunocytochemical as well as morphological criteria before classifying cells as tumour cells (Berger et al., 1988) . There are reports that anti-cytokeratin antibodies are less sensitive in recognising breast cancer metastases than anti-EMA (Thor et al., 1988) . Therefore, we used an additional antibody (12-H-12) that does not stain lymphoid cells (Kaul et al., 1989) as a parallel control: cells were only classified as tumour cells if they stained positively with the anti-EMA/anti-cytokeratin cocktail as well as 12-H-12.
Another factor contributing to our detection rate might be the use of six aspiration sites (Coombes et al., 1983 (1991) , it might be advisable for future studies of more patients to include this factor. The question of whether detected tumour cells are actually micrometastases or whether they are shed by the primary tumour or seeded during surgery without bearing any further clonogenic potential has been raised in the literature (Mansi et al., 1989) . In a median interval of 13 months after primary surgery, we repeated marrow aspirates in three initially tumour cell-negative patients: all of them have remained tumour cell-negative, and up until now none of them has relapsed. Porro et al. (1988) aspirated bone marrow in 11 of their patients before as well as after primary surgery. None of these patients had a different result after surgery. Thus, they were able to rule out possible tumour cell spread due to surgical manipulation. Yet another argument against a merely artificial spread of tumour cells by surgical intervention is the fairly constant percentage of tumour cell detection in the literature, whether bone marrow aspirates are taken immediately before (Mansi et al., 1987; Porro et al., 1988; Cote et al., 1991) or after (Harbeck et al., 1987; Diel et al., 1992) primary surgery. In our opinion, multiple aspiration sites as well as the use of cocktails of monoclonal antibodies are likely to play a far more important role in an increased detection rate. To examine the viability of the detected tumour cells, we developed a method for establishing cell cultures from the marrow aspirates. So far we have succeeded in growing cell cultures from one tumour cell-positive patient. The identity of the observed clones was proven immunocytochemically. In addition to these laboratory experiments, the follow-up data presented by our group, in accordance with other groups, strongly suggest that a large proportion of these cells may be viable and clonogenic. In our study the relapse rate among tumour cell-positive patients was almost three times that of tumour cell-negative patients.
Our follow-up data over a 5-year period confirm that tumour cell detection in the bone marrow of primary breast cancer patients is a statistically significant prognostic factor for early relapse. Its prognostic value is even higher in predicting bone metastases. Tumour cell-positive patients also seem to have a worse prognosis with regard to overall survival, although this trend is not yet significant. Even within a subgroup defined by 'established' prognostic factors such as oestrogen receptor-positive patients, tumour cell presence characterises high-risk patients for a significantly shorter relapse-free as well as overall survival. In a multivariate setting, tumour cell presence is a statistically significant prognostic factor for relapse-free as well as overall survival. Its prognostic impact outweighs even that of a clinically important, 'established' prognostic factor such as lymph node status. Cote et al. (1991) also found tumour cell presence to be a better predictor for early recurrence than lymph node status. Mansi et al. (1991) reported after a median follow-up of 76 months that tumour cell detection was a significant prognostic factor for relapse-free as well as overall survival. However, their multivariate analysis showed that this prognostic impact was less than that of tumour size or nodal status.
In contrast to other researchers (Mansi et al., 1992; Diel et al., 1992) , we did not obtain a statistically significant correlation between tumour cell detection and 'established' prognostic factors. However, the role of vascular invasion (Mansi et al., 1987) was not evaluated. In our study, keeping in mind that the numbers in some subgroups are still small, tumour cell presence appears to be an independent prognostic factor. Tumour cell-positive patients seem to be fairly evenly distributed among the various risk groups, i.e. no excess of tumour cell-positive patients in a particular risk group was detected. However, there is one somewhat unexpected exception: the percentage of tumour cell-positive patients is even higher among node-negative patients (49%) than among node-positive patients (36%). The follow-up data of the node-negative patients resemble those of the total 100 MO patients: tumour cell-positive patients tend to have a worse prognosis with shorter relapse-free as well as overall survival. Porro et al. (1988) also reported a higher detection rate in node-negative patients, although the difference in their study is not as evident: 17% vs 14%. Our results tend to confirm their theoretical considerations. By examining bone marrow aspirates, one may discover an alternative route for metastasis that bypasses the axillary lymph nodes via the bloodstream. Thus, there might be two independent but equivalent routes for metastatic spread in breast cancer (Fisher et al., 1989b) . This concept, together with the presented follow-up data, emphasises the importance of bone marrow aspirates for identifying an additional risk group of patientsespecially among node-negative patients -that might have been missed by sole consideration of the established prognostic factors. Our study also suggests that node-positive, tumour cell-positive patients might benefit from a more intensive form of adjuvant therapy (e.g. high-dose chemotherapy).
Methodological improvements need to be made, since the detection method is still too time-consuming for routine application. Further clinical studies, perhaps on the basis of national or international collaborations, are warranted in order to confirm the international follow-up results presented so far: Only larger patient groups and longer follow-up periods will allow more detailed subgroup analyses, in particular among node-negative patients. Such studies will help to decide whether tumour cell presence is an important prognostic factor by itself or whether it is of more value in a panel of prognostic factors (McGuire et al., 1990) . A multicentre study has now been proposed in Germany in which nodenegative, tumour cell-positive patients will be randomised to receive adjuvant therapy or not (Funke et al., 1991) . The results of this trial will determine whether adjuvant therapy is beneficial in patients with tumour cells in their bone marrow.
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